Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin’s disease: Comparison with combined-modality therapy

Bone Marrow Transplantation

Volumn 29, Issue 10, 2002, Pages 833-842

  Vigouroux, S ^a   Milpied, N ^a   Andrieu, J M ^b   Colonna, P ^b   Ifrah, N ^c   Colombat, P ^d   Desablens, B ^e   Abgrall, J F ^f   Casassus, P ^g   Guilhot, F ^h   Briere, J ⁱ   Le Mevel, A ^j   Moreau, P ^a   Mechinaud, F ^a   Mahe, B ^a   Morineau, N ^a   Vigier, M ^a   Rapp, M J ^a   Harousseau, J L ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

^e AMIENS UNIVERSITY HOSPITAL   (France)

^f BREST UNIVERSITY HOSPITAL   (France)

^g University Hospital   (France)

^h POITIERS UNIVERSITY HOSPITAL   (France)

ⁱ BEAUJON HOSPITAL   (France)

^j Centre Anti cancéreux   (France)

more..

Author keywords

Autologous stem cell transplantation; Combined modality treatment; First line treatment; Hodgkin's disease

Indexed keywords

BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; VINBLASTINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; FRANCE; HEART DISEASE; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INTERMETHOD COMPARISON; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TUMOR VOLUME; WHOLE BODY RADIATION; AGED; AUTOTRANSPLANTATION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRESCHOOL CHILD; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; COMPARATIVE STUDY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; MALE; MIDDLE AGE; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION; HUMANS; MIDDLE AGED;

EID: 0035998360     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703547     Document Type: Article

References (40)

1. Cancer statistics 1998
2. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
3. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease
4. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy
5. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT
6. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry
7. Early intensive therapy with autologous stem cell transplantation in high-risk Hodgkin's disease: Long-term follow-up in 35 cases
8. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy
9. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: Ten-year results of the Paris-Ouest-France 81/12 patients
10. Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages
11. Bulky Hodgkin's disease: Treatment with an initial 7-drug chemotherapy delivered over 12 weeks followed by high-dose extended field irradiation. Seven-year results of the Goelams H90M multicentric randomized Ntrial
12. High-risk Hodgkin's disease (HD): ABVD chemotherapy (4 cycles) followed by BEAM-conditioned autologous stem cell transplantation (ASCT) and focal radiotherapy (RT) versus intensive chemotherapy (3 cycles) followed by RT (IF-RT). Two-year results of the GOELAMS H97-GM multicentric randomized trial
13. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting
14. High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease
15. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission
16. A prognostic score for advanced Hodgkin's disease
17. Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: A multivariate analysis comparing two specialist treatment centres
18. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis
19. Increasing interdependency of prognosis- and therapy-related factors in Hodgkin's disease
20. Treatment of localized forms of Hodgkin's disease with 3 courses of chemotherapy (ABVD-MP) in combination with wide focal and prophylactic lumbo-splenic radiotherapy. The POF 81/12 protocol
21. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy
22. Early response to chemotherapy as a prognostic factor in Hodgkin's disease
23. Predictive value of the early response to chemotherapy in high-risk stages II and III Hodgkin's disease
24. Prognostic value of response after three MOPP cycles in Hodgkin's disease-stage III and IV
25. Prognostic role of the early response to chemotherapy in advanced Hodgkin's disease
26. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
27. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alterning with ABVD
28. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's lymphoma study group
29. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot study E1492
30. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: Interim results from the ongoing EORTC-LCG and GMPC phase III trial
31. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
32. High-risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure
33. High-dose BEAM chemotherapy with autologous haematopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML
34. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience
35. Second cancer among long-term survivors from Hodgkin's disease
36. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease
37. Risk of second cancers after treatment for Hodgkin's disease
38. Breast cancer after treatment of Hodgkin's disease
39. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease